GHK-Cu: What the Research Says About the Copper Peptide
Glycyl-L-histidyl-L-lysine, almost always written as GHK, is among the smallest molecules to have sustained five decades of laboratory attention. It is a three-residue peptide that occurs naturally in human plasma, and it binds copper(II) with sufficient avidity that the copper-bound form — GHK-Cu — is generally regarded as the biologically relevant species. That combination of extreme structural simplicity and a coordinated transition metal has made it a recurring subject in connective-tissue biochemistry, wound-repair models and, more recently, transcriptomics.
This article summarises what the published literature reports about GHK-Cu: its chemistry, the experimental findings most often cited, the limitations of that evidence base, and the handling and verification considerations that matter when the compound is used as a laboratory reference material. Nothing here describes use in humans or animals outside of the published studies referenced.
A tripeptide with an unusual affinity for copper
The free tripeptide has the sequence glycine–histidine–lysine, molecular formula C14H24N6O4 and a molecular weight of approximately 340.4 g/mol. Copper coordination is what distinguishes it. The Cu(II) ion is held by a set of donor atoms contributed by the peptide backbone and side chains — the terminal amine nitrogen, the deprotonated amide nitrogen between glycine and histidine, and the imidazole nitrogen of the histidine residue — with the lysine side chain and solvent completing the coordination environment. The complex is commonly catalogued under CAS 49557-75-7 and is visually distinctive: solutions and lyophilised powder carry a blue tint characteristic of copper(II) coordination compounds.
Pickart and Margolina, reviewing the field in International Journal of Molecular Sciences (2018), describe GHK's affinity for Cu(II) as comparable to that of the N-terminal copper transport site of serum albumin. That comparison matters mechanistically, because it implies GHK can plausibly participate in copper exchange with the major plasma copper carrier rather than simply sequestering the metal. Much of the interpretive framework applied to GHK-Cu in the literature rests on this idea of the peptide as a copper shuttle rather than as a conventional receptor ligand.
Discovery and the reported decline with age
GHK was first isolated by Loren Pickart in the early 1970s from a fraction of human plasma while investigating factors that altered the behaviour of hepatic tissue in culture. Subsequent work characterised the tripeptide and its copper complex, and Pickart's group and others have since published extensively on it.
One frequently repeated observation is that plasma GHK concentration declines with age. Figures cited in the review literature place it at roughly 200 ng/mL in early adulthood, falling to approximately 80 ng/mL by around age sixty. This decline is descriptive: it is an association reported in the peptide literature, not a demonstration that the change causes any particular physiological outcome. It has nonetheless framed much of the subsequent research question — namely whether restoring GHK availability in an experimental system reproduces the tissue behaviour seen in younger tissue.
Extracellular matrix remodelling in cell and animal models
The most concrete body of evidence concerns connective tissue. Maquart and colleagues reported in FEBS Letters (1988) that the copper complex stimulated collagen synthesis in cultured fibroblasts at very low concentrations, on the order of picomolar to nanomolar.
The most-cited in vivo work is Maquart, Bellon, Gillery and co-workers in the Journal of Clinical Investigation (1993), using the Schilling wound-chamber model in rats. Stainless steel mesh cylinders were implanted subcutaneously and injected sequentially with either saline or GHK-Cu at several concentrations. Chambers receiving the peptide showed concentration-dependent increases in dry weight, DNA, total protein, collagen and glycosaminoglycan content. Notably, the stimulation of collagen synthesis was roughly twice that of non-collagen protein synthesis, indicating a degree of selectivity rather than a general increase in protein output. Type I and type III collagen mRNAs rose, while TGF-β mRNA did not, and the relative proportion of dermatan sulfate increased. A structurally unrelated control tripeptide, L-glutamyl-L-histidyl-L-proline, produced no significant effect — an internal control that argues against the result being a nonspecific peptide or copper artefact.
Complementary work published in the Journal of Investigative Dermatology examined the degradative side of the same system, reporting that GHK-Cu modulates the expression and activation of matrix metalloproteinases in wounds, alongside separate work on glycosaminoglycan and small proteoglycan expression. Taken together, these papers describe a molecule that appears in these models to influence both matrix deposition and matrix turnover rather than acting on synthesis alone. Pollard and colleagues (Archives of Facial Plastic Surgery, 2005) separately examined the copper tripeptide's effects on the growth and growth-factor expression of normal and irradiated fibroblasts in culture.
Gene-expression studies broadened the picture
Interest in GHK expanded considerably once transcriptomic screening methods became available. Hong and colleagues (2010) used the Broad Institute's Connectivity Map — a database of transcriptional responses to bioactive compounds — and reported that GHK was the most active of 1,309 substances screened in reversing the expression pattern of a 54-gene signature associated with aggressive early-stage mismatch-repair colorectal cancer, at a low micromolar concentration.
Campbell and colleagues took a similar approach in Genome Medicine (2012). Profiling 64 lung-tissue samples drawn from eight regions each of eight lungs from smokers with COPD, they identified 127 genes whose expression tracked with the local severity of emphysematous destruction. Genes rising with destruction were enriched for inflammatory signalling; genes falling were enriched for tissue-repair processes including the TGF-β pathway, actin organisation and integrin signalling. Querying the Connectivity Map with that signature returned GHK as a compound predicted to reverse it, and follow-up experiments in fibroblasts were consistent with that prediction.
Pickart and Margolina's 2018 review consolidated this literature and reported that GHK influences the expression of more than 4,000 human genes across categories spanning tissue remodelling, antioxidant defence and inflammatory signalling. That figure is often quoted without its context, so it is worth stating plainly: transcriptional signature reversal identified computationally is a hypothesis-generating result. It indicates that a compound shifts gene expression in a direction opposite to a disease-associated pattern in a screening dataset. It is not evidence of a clinical effect, and the studies themselves do not claim otherwise.
More recent experimental work
Research on GHK-Cu has continued in animal disease models. A 2025 paper in Frontiers in Pharmacology examined the peptide in dextran sulfate sodium-induced colitis in BALB/c mice, reporting reductions in disease activity index scores relative to untreated DSS controls and proposing involvement of SIRT1/STAT3 signalling and a reduction in Th17 cell numbers, assessed by Western blot and histological staining. As with the earlier literature, this is a rodent model result. It describes what happened in mice under defined experimental conditions and supports further preclinical investigation rather than any conclusion about other species.
Practical considerations for laboratory handling
GHK-Cu is supplied as a lyophilised powder with a characteristic blue colouration. Several handling points follow from its being a metal complex rather than a plain peptide.
- Chelators strip the copper. Buffers containing EDTA or other strong chelating agents will compete for Cu(II) and can dissociate the complex, leaving free GHK. Buffer selection matters more here than for uncomplexed peptides.
- pH affects complex stability. The coordination chemistry depends on deprotonated amide nitrogen donation, so strongly acidic conditions favour dissociation.
- Copper complexes are redox-active. Prolonged exposure to light, oxygen and elevated temperature should be minimised, and solutions should not be assumed indefinitely stable.
- Freeze–thaw cycling degrades peptides generally. Aliquoting reconstituted material avoids repeated cycling of a single vial.
General cold-chain and reconstitution practice applies as it does to any lyophilised peptide; our separate guide to peptide storage and handling covers the underlying principles in more detail.
Verifying identity and purity
Analytical verification of a copper complex requires slightly more thought than for a simple peptide. Reversed-phase HPLC establishes chromatographic purity of the peptide component, and mass spectrometry confirms the identity of the tripeptide by molecular mass. Neither, on its own, characterises the copper stoichiometry — that is a separate question, and the presence of the expected blue colouration is a crude visual indicator rather than an analytical one. Reviewing a full certificate of analysis, including the chromatogram itself rather than only the summary purity figure, is the practical minimum; our guide to reading a peptide COA sets out what to look for. Third-party analytical documentation for our catalogue is published on the Lab Results page.
What remains unresolved
The GHK-Cu literature is unusual in being both long-running and heavily weighted toward in vitro and rodent work. Several questions remain genuinely open. The transcriptomic findings are computational predictions with limited experimental follow-up. Bioavailability and stability under different delivery conditions are incompletely characterised. The relationship between the peptide's matrix effects and its copper-shuttling role has not been cleanly separated — it is not always clear whether an observed result reflects GHK, copper, or the specific complex. And the interaction between exogenous GHK-Cu and systemic copper homeostasis, which is tightly regulated, is not well described in the published work.
For laboratories using GHK-Cu as a reference compound, those gaps are the interesting part: they define where the remaining experimental questions sit.
Research use only. Not a medicine, supplement or therapeutic good. Not for human or veterinary consumption.